Glaxo hopes for pandemic flu vaccine by yr-end

	Tweet

GlaxoSmithKline Plc plans to start final clinical trials in a bid to find a vaccine against pandemic flu, which experts fear may be triggered by bird flu, its chief executive Jean-Pierre Garnier said.

In an interview to be broadcast on the News24 channel of Britain’s Broadcasting Corp. (BBC) later on Wednesday, Garnier said the company hopes to produce the new vaccine by the end of this year.

“We are announcing that we are starting the final clinical trials in a few weeks so that by Christmas we might be in a position to produce large quantities of this pandemic vaccine,” Garnier is quoted as saying in a transcript of the interview.

However, Garnier said it was difficult to say how effective the new vaccine would be given that it was as yet unclear how the H5N1 virus would develop.

“It’s all a question of mutation,” Garnier said.

“If the mutation is a slight variation on H5N1 the vaccine is likely to be effective...But if it’s a wide mutation, where the new virus is systematically different from H5N1 then...the vaccine is not going to be effective,” Garnier was quoted as saying.

On Jan. 6, Glaxo said it had submitted a dossier to European healthcare regulators seeking outline approval to market a vaccine against pandemic flu, the first vaccine manufacturer to do so under new European rules designed to fast-track potential pandemic flu shots.

Glaxo is one several companies working to develop a vaccine against the H5N1 strain of virus. 

RELATED STORIES:
Chinese companies to make Viagra variant after Pfizer loses patent   FDA advisers back first drug to prevent HIV   Australia’s medicines regulator close to decision on herceptin   Pfizer to pay penalty for chemical release   Reformulated Imatinib Eliminates Morphine Tolerance in Lab Studies   Key senator vows work on diet supplement bill   Drug resistant H1N1 no major change in virus: WHO   New drug for Crohn’s disease gives mixed results   Meningitis Drug Shortages Possible   Europe orders full safety probe of Cox-2 drugs   Painkiller Vioxx Often Taken at Too High Dose   Court upholds Vioxx class action against Merck

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]